Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Oncology · Malignant Ascites

Gastric Cancer Fluid Buildup: How is Ascites Treated?

At a Glance

Malignant ascites in advanced gastric cancer is primarily treated by physically draining the abdominal fluid through paracentesis or a home catheter for immediate symptom relief. Medical therapies like systemic chemotherapy are then used to treat the underlying cancer causing the fluid buildup.

When advanced diffuse gastric adenocarcinoma spreads to the lining of the abdominal cavity (the peritoneum), it can cause a condition known as peritoneal carcinomatosis [1]. This spread severely irritates the tissues and disrupts your normal fluid balance, leading to a massive buildup of fluid in the belly known as malignant ascites [2]. The primary ways your care team will treat this are by physically draining the fluid for immediate comfort, helping you manage nutrition and hydration, and applying cancer-directed therapies (like chemotherapy) to treat the underlying tumors causing the problem.

Understanding the Fluid Buildup

The abdomen is lined by a membrane called the peritoneum, which naturally produces a small amount of fluid to keep your internal organs lubricated. When diffuse gastric cancer cells spread to this lining, they trigger an inflammatory response that causes blood vessels to leak excess fluid [2]. Simultaneously, the tumors block the lymphatic system—the body’s natural drainage network—preventing the excess fluid from being cleared away [1].

Because the body cannot absorb the fluid as fast as it is produced, the abdomen swells. This can cause significant physical discomfort, shortness of breath from pressure on the diaphragm, and early satiety (feeling extremely full after eating very little).

Immediate Relief: Draining the Fluid

For most patients, the most effective way to relieve the pressure and discomfort is by physically removing the extra fluid.

  • Therapeutic Paracentesis: This is a common procedure for immediate symptom relief. A doctor numbs the skin and uses a small needle and catheter to draw out the excess fluid—often removing several liters at a time [3]. While this brings fast relief to your breathing and stomach, it is important to know that ascitic fluid is full of protein. Draining large volumes removes essential proteins and electrolytes from your body. You will likely experience profound fatigue, dizziness, or a temporary drop in blood pressure afterward, so plan to rest for the remainder of the day. There is also a rare risk of infection or bleeding. Because the fluid often re-accumulates, the procedure may need to be repeated.
  • Indwelling Peritoneal Catheters: If your fluid builds up rapidly and you require frequent draining, your doctor might suggest placing a permanent, tunneled tube (such as a PleurX or Tenckhoff catheter) [4][5]. This allows you or a caregiver to drain the fluid safely at home, significantly reducing the need for exhausting, repeated hospital visits [6][7]. When placed with proper training and hygiene protocols, these devices are safe and have a low risk of infection [8][9].

Important Daily Management Tips

  • Do Not Stop Drinking Fluids: Because your belly is filling with fluid, your immediate instinct might be to restrict your water intake to stop the swelling. However, drinking water does not cause malignant ascites. Restricting fluids will only lead to dangerous dehydration and kidney strain. Drink enough to stay hydrated unless your doctor explicitly tells you otherwise.
  • Adjusting How You Eat: The fluid presses heavily against your stomach, causing early satiety. Combined with the protein lost during fluid drainages, you are at a high risk for malnutrition and muscle wasting. Switch to eating small, frequent, high-protein meals rather than three large ones. Your doctor may also recommend consulting a registered dietitian to ensure you are meeting your nutritional needs.

Medications: Are Water Pills (Diuretics) Helpful?

Patients with fluid buildup from liver or heart failure are often prescribed diuretics (water pills) to help the kidneys flush out extra fluid. However, malignant ascites behaves very differently.

Because the fluid buildup in advanced gastric cancer is driven by tumor irritation and blocked lymphatic drainage rather than kidney or heart issues, standard diuretics are generally much less effective [10]. There is no established medical consensus supporting the routine use of diuretics for malignant ascites, and they can sometimes carry risks of dehydrating your body or straining your kidneys [11]. Your care team will carefully evaluate whether a trial of diuretics is safe and appropriate for your specific situation.

Treating the Root Cause: Cancer-Directed Therapies

While draining fluid manages the immediate physical symptoms, slowing down the production of the fluid requires treating the cancer cells in the peritoneal lining.

  • Systemic Chemotherapy: Intravenous (IV) chemotherapy travels throughout the body and can help shrink the tumors in the abdomen. Effective systemic treatment can delay the worsening of ascites and help stabilize the disease [12][13].
  • Targeted Therapies: Certain proteins, like the Vascular Endothelial Growth Factor (VEGF), promote the growth of abnormal blood vessels that leak fluid into the abdomen [14]. Therapies that block these specific pathways can sometimes play a role in managing peritoneal spread [15][16].
  • Regional Therapies: You may read online about treatments that deliver heated chemotherapy directly into the abdomen during a massive surgery, a procedure known as HIPEC [17][18]. It is critical to know that this is only an option for a very small minority of patients with highly limited peritoneal spread [19][20]. Patients who have already developed severe, large-volume malignant ascites are almost universally not candidates for this extensive surgery, as the body cannot handle the physical stress. However, less invasive regional approaches, like delivering chemotherapy directly into the fluid through a port, are sometimes explored in specialized centers or clinical trials [12].

Managing malignant ascites requires a highly individualized approach. Your care team will balance treatments designed to control the cancer with palliative interventions focused strictly on keeping you comfortable, protecting your nutrition, and allowing you to breathe easily.

Common questions in this guide

Should I stop drinking water if I have ascites from gastric cancer?
No, you should not restrict your water intake unless instructed by your doctor. Malignant ascites is caused by cancer cells irritating the abdomen, not by drinking too much fluid. Restricting water can lead to dangerous dehydration and kidney strain.
What is the fastest way to relieve fluid buildup in my abdomen?
The most immediate relief comes from a therapeutic paracentesis, a procedure where a doctor uses a small needle to drain the excess fluid. If fluid builds up rapidly and frequently, a permanent catheter can be placed so you can drain the fluid at home.
Are water pills (diuretics) helpful for malignant ascites?
Diuretics are generally much less effective for fluid buildup caused by advanced gastric cancer compared to fluid buildup from heart or liver issues. They do not treat the root cause of malignant ascites and can sometimes risk dehydrating your body.
How should I change my diet when I have severe belly swelling?
The fluid presses against your stomach, making you feel full quickly and putting you at risk for malnutrition. It is best to eat small, frequent, high-protein meals instead of three large ones to help replace the proteins lost during fluid drainage.
Am I a candidate for HIPEC surgery if I have massive fluid buildup?
HIPEC is generally not an option for patients who have developed severe, large-volume malignant ascites. The procedure is extremely physically demanding, and the body typically cannot handle the stress of this extensive surgery at this stage of the disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.At what frequency of fluid draining should we discuss placing a permanent catheter, like a PleurX, instead of repeating paracentesis?
  2. 2.What are my current albumin and protein levels, and do I need specialized nutritional supplements to replace what is lost during fluid drains?
  3. 3.Is a trial of diuretics safe for my kidneys right now, or should we avoid them given the nature of malignant ascites?
  4. 4.Could my current systemic chemotherapy regimen be adjusted to better target the fluid production?
  5. 5.What specific symptoms—such as a fever, sudden sharp abdominal pain, or extreme dizziness—mean I should go to the emergency room immediately?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.

    Lim B, Kim C, Kim JH, et al.

    Oncotarget 2016; (7(7)):8055-66 doi:10.18632/oncotarget.6977.

    PMID: 26811494
  2. 2

    Macrophage-mediated vascular permeability via VLA4/VCAM1 pathway dictates ascites development in ovarian cancer.

    Zhang S, Xie B, Wang L, et al.

    The Journal of clinical investigation 2021; (131(3)).

    PMID: 33295887
  3. 3

    Use of indwelling pleural/peritoneal catheter in the management of malignant ascites: a retrospective study of 48 patients.

    Chan KP, Badiei A, Tan CPS, et al.

    Internal medicine journal 2020; (50(6)):705-711 doi:10.1111/imj.14642.

    PMID: 31566871
  4. 4

    Central Venous Catheter as Peritoneal Indwelling Catheter for the Management of Recurrent Malignant Ascites: A Case Series.

    Ratre BK, Suvvari P, Hoda W, et al.

    Indian journal of palliative care 2019; (25(1)):57-60 doi:10.4103/IJPC.IJPC_145_18.

    PMID: 30820103
  5. 5

    Permanent indwelling peritoneal catheters for palliation of refractory ascites in end-stage liver disease: A systematic review.

    Macken L, Hashim A, Mason L, Verma S

    Liver international : official journal of the International Association for the Study of the Liver 2019; (39(9)):1594-1607 doi:10.1111/liv.14162.

    PMID: 31152623
  6. 6

    Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter.

    Meier M, Mortensen FV, Madsen HH

    Acta radiologica open 2015; (4(7)):2058460115579934 doi:10.1177/2058460115579934.

    PMID: 26346641
  7. 7

    Management of Malignant Ascites by Indwelling Tunnelled Catheters in Indian Setup: A Case Series.

    Suvvari P, Nair A, Mantha SSP, et al.

    Indian journal of palliative care 2021; (27(2)):349-353 doi:10.25259/IJPC_416_20.

    PMID: 34511807
  8. 8

    A safe and effective treatment for refractory malignant ascites: the use of pigtail catheters.

    Doğan A, Aydıner Ö

    Polish journal of radiology 2024; (89()):e561-e565 doi:10.5114/pjr/194651.

    PMID: 39850401
  9. 9

    Safety and Effectiveness of Palliative Tunneled Peritoneal Drainage Catheters in the Management of Refractory Malignant and Non-malignant Ascites.

    Knight JA, Thompson SM, Fleming CJ, et al.

    Cardiovascular and interventional radiology 2018; (41(5)):753-761 doi:10.1007/s00270-017-1872-1.

    PMID: 29344716
  10. 10

    [Supportive care for malignant ascites in palliative phase: Place of paracentesis and diuretics].

    Gamblin V, Da Silva A, Villet S, El Hajbi F

    Bulletin du cancer 2015; (102(11)):940-5.

    PMID: 26477275
  11. 11

    Advances in the treatment of malignant ascites in China.

    Zhang J, Qi Z, Ou W, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2024; (32(2)):97 doi:10.1007/s00520-023-08299-w.

    PMID: 38200158
  12. 12

    Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials.

    Gallanis AF, Perati SR, Canady SN, et al.

    Annals of surgical oncology 2026; (33(5)):4679-4689 doi:10.1245/s10434-025-18967-2.

    PMID: 41545610
  13. 13

    Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites.

    Ni X, Wu P, Wu J, et al.

    Oncology letters 2017; (14(2)):1691-1696 doi:10.3892/ol.2017.6342.

    PMID: 28789396
  14. 14

    Diagnostic value of vascular endothelial growth factor (VEGF) levels in gastrointestinal cancers with ascites - A cross sectional study.

    Samuel EMK, Sundaramurthi S, Hanumanthappa N, Nelamangalaramakrishnaiah VP

    Turkish journal of surgery 2025; (41(1)):78-84 doi:10.47717/turkjsurg.2025.6592.

    PMID: 40012327
  15. 15

    Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.

    Kasai S, Kuwayama N, Motoo Y, et al.

    Biochemical and biophysical research communications 2022; (600()):80-86 doi:10.1016/j.bbrc.2022.02.045.

    PMID: 35196631
  16. 16

    The clinical significance of vascular endothelial growth factor in malignant ascites.

    Zhan N, Dong WG, Wang J

    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016; (37(3)):3719-25 doi:10.1007/s13277-015-4198-0.

    PMID: 26462841
  17. 17

    Conversion Surgery for Patients with Advanced Gastric Cancer with Peritoneal Carcinomatosis.

    Lee TY, Liao GS, Fan HL, et al.

    Journal of oncology 2021; (2021()):5459432 doi:10.1155/2021/5459432.

    PMID: 34804160
  18. 18

    Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites.

    Jiao J, Li C, Yu G, et al.

    World journal of surgical oncology 2020; (18(1)):180 doi:10.1186/s12957-020-01956-y.

    PMID: 32698824
  19. 19

    Surgical management of stage IV gastric adenocarcinoma: A systematic review and expert recommendations from the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) and the Spanish Association of Surgeons (AEC).

    Jimenez-Fonseca P, Bruna M, Gallego J, et al.

    Cirugia espanola 2026; (104(2)):800254 doi:10.1016/j.cireng.2025.800254.

    PMID: 41276253
  20. 20

    Prophylaxis and treatment of peritoneal carcinomatosis of gastric origin using hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis of randomized trials.

    Stefano M, Perrina D, Vallicelli C, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2024; (28(7)):1185-1193 doi:10.1016/j.gassur.2024.04.007.

    PMID: 38599315

This information is for educational purposes only and does not replace professional medical advice. Always consult your oncology team for personalized guidance on managing ascites and safely performing fluid drainage.

Get notified when new evidence is published on diffuse gastric adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.